Amsterdam UMC Stichting
Amsterdam UMC Stichting is recorded as a service provider in 25 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 25 trials · Latest update first
HOVON 127 BL / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
Sponsor Haemato Oncology Foundation For Adults Netherlands
- Start (EU)
- Latest update
- Estimated end
HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (RED RIVER CLL)
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Efficacy and Tolerability of Fixed Duration Teclistamab and Talquetamab for Frail Patients with Newly Diagnosed Multiple Myeloma (2 Cohort Study) - the EMN 37 FITFIX FOR FRAIL Trial
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
MRD registry and multicenter, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients with AML or CLL (RESOLVE trial).
Sponsor Medizinische Hochschule Hannover
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 173 AML: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
Saracatinib trial TO Prevent FOP
Sponsor Stichting Amsterdam UMC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
A single-center, randomized, double-blind, placebo-controlled, parallel-group, proof-of-concept trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis
Sponsor Idorsia Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson’s disease
Sponsor AC Immune S.A.
- Start (EU)
- Latest update
- Estimated end
EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)
Sponsor Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
- Start (EU)
- Latest update
- Estimated end
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia
Sponsor Exciva GmbH
- Start (EU)
- Latest update
- Estimated end
HOVON 139 CLL: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of Gazyvaro (obinutuzumab) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. (GIVE trial).
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstrom’s macroglobulinemia
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
HOVON 176: Golcadomide (CC-99282) for relapsed and refractory primary large B-cell lymphoma of the central nervous system and secondary central nervous system lymphoma: a phase 2 study
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 159 CLL: REtreatment with VEnetoclax and Acalabrutinib after venetoclax Limited duration (REVEAL) A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed after first line venetoclax + anti-CD20 mAb treatment for chronic lymphocytic leukemia (CLL or SLL)
Sponsor Haemato Oncology Foundation For Adults Netherlands
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Amsterdam UMC Stichting?
The 2026-10-09 snapshot links Amsterdam UMC Stichting to 25 distinct CTIS trials. Recorded services include Laboratory services, Biobanking, MRD, biomarker and immunological studies, Pathology review, among 14 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Amsterdam UMC Stichting?
The most frequently recorded therapeutic areas are Haematological Malignancies, Neurology, Genetic and Congenital Disorders, Musculoskeletal. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Amsterdam UMC Stichting conducted?
The linked trials record locations in 20 countries, including Netherlands, Belgium, Germany, Denmark, Spain. These are trial locations, not confirmed office locations or countries where Amsterdam UMC Stichting delivered services.
What can this page tell me about Amsterdam UMC Stichting's trial experience?
Browse 25 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Amsterdam UMC Stichting. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Amsterdam UMC Stichting